Skip to content
10-Q

Quarterly Report

Connect Biopharma Holdings Ltd CNTB

0001835268-25-000035

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 55.56M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $36.29M
Short Term Investments Q1 2025 · Dec 31, 2024 $15.48M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $47.71M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $78.23M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.57M
Current Liabilities Q1 2025 · Dec 31, 2024 $8.46M
Total Liabilities Q1 2025 · Mar 31, 2025 $9.79M
Total Liabilities Q1 2025 · Dec 31, 2024 $9.12M
Current Assets Q1 2025 · Mar 31, 2025 $87.76M
Current Assets Q1 2025 · Dec 31, 2024 $96.96M
Total Assets Q1 2025 · Mar 31, 2025 $92.69M
Total Assets Q1 2025 · Dec 31, 2024 $101.28M
Shares Diluted Q1 2025 · Mar 31, 2024 55.1M sh
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$591K
Stockholders Equity Q1 2025 · Mar 31, 2024 $93.9M
Stockholders Equity Q1 2025 · Dec 31, 2023 $101.5M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.16
Eps Basic Q1 2025 · Mar 31, 2024 −$0.16
Sga Expense Q1 2025 · Mar 31, 2024 $3.97M
Rd Expense Q1 2025 · Mar 31, 2024 $8.66M
Net Income Q1 2025 · Mar 31, 2024 −$8.69M
Operating Income Q1 2025 · Mar 31, 2024 −$12.63M